ABC Overview

Cencora vs. Cardinal Health: Jim Cramer expresses a preference for Cardinal Health over Cencora, indicating that he believes Cardinal Health outperforms Cencora in the market.

Investment Advice: Cramer advises selling a stock before concluding the conversation, suggesting a proactive approach to investment decisions.

Perpetua Resources: While acknowledging Perpetua Resources as a popular stock, Cramer recommends considering Agnico instead, indicating a shift in focus.

Resources for Investors: Cramer promotes his free Guide to Investing and encourages sign-ups for the CNBC Investing Club to keep track of his market strategies.

Appointment of John R. Palumbo: Lucid Diagnostics Inc. has appointed John R. Palumbo, a seasoned healthcare executive with 40 years of experience, to its Board of Directors, effective September 22, 2025. His expertise in guiding early-stage companies and extensive network is expected to be valuable for Lucid's growth.

Focus on Cancer Prevention: Lucid Diagnostics is dedicated to cancer prevention, particularly for patients with gastroesophageal reflux disease (GERD). The company offers the EsoGuard Esophageal DNA Test, aimed at early detection of esophageal precancer, representing a significant advancement in cancer prevention tools.